Eli Lilly Stock Stumbles on FDA Rejection

Options Bears are targeting LLY at double the intraday average

Deputy Editor
Jan 20, 2023 at 11:15 AM
facebook twitter linkedin

The U.S. Food and Drug Administration (FDA) rejected the accelerated approval of Eli Lilly and Co's (NYSE:LLY) experimental Alzheimer's drug due to a lack of enough trial data from patients treated for at least a year. Jefferies called this setback a "modest positive" for rival Biogen (BIIB). 

At last glance, Eli Lilly stock was down 1.2% at $347.01, earlier as low as $344.58. The stocks 100-day moving average kept losses in check, however. Year-over-year, LLY is outperforming with a 42.7% year-over-year lead. 

The majority of analysts are bullish on LLY, with 14 of the 16 in coverage carrying a "buy" or better rating. Plus, the 12-month consensus price target of $389.52 is a 12.3% premium to current levels. 

Options bears are targeting LLY after today's news. So far, 3,121 puts have been exchanged, which is double what's seen at this point. The weekly 3/3 320-strike put is the most popular, where new positions are being sold to open. 


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners